FDG PET and Split-Bolus Multi–Detector Row CT Fusion Imaging in Oncologic Patients: Preliminary Results

Scialpi, Michele; Palumbo, Isabella; Gravante, Sabrina; Buresta, Tommaso; D’Andrea, Alfredo; Pierotti, Luisa; Palumbo, Barbara

doi:10.1148/radiol.2015150151

Cited by 4 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Distant involvement such as lung, bone, peritoneal and adrenal metastasis was categorized as an individual site. A positive lesion was considered when met the following criteria [ 19 ]: (i) a focal area had abnormally elevated 18 F-FDG or 18 F-FAPI uptake, accompanied by the abnormal density/signal in the corresponding sites on CT/MRI; and (ii) the lesions had typical features from contrast-enhanced CT (ceCT) or ce-MRI.…”

Section: Methodsmentioning

confidence: 99%

Head-to-head comparison of 18F-FAPI and 18F-FDG PET/CT in staging and therapeutic management of hepatocellular carcinoma

Zhang,

Jiang,

et al. 2023

Cancer Imaging

View full text Add to dashboard Cite

Background Fluorine 18 (18F) fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) has limitations in staging hepatocellular carcinoma (HCC). The recently introduced 18F-labeled fibroblast-activation protein inhibitor (FAPI) has shown promising prospects in detection of HCC lesions. This study aimed to investigate the initial staging and restaging performance of 18F-FAPI PET/CT compared to 18F-FDG PET/CT in HCC. Methods This prospective study enrolled histologically confirmed HCC patients from March 2021 to September 2022. All patients were examined with 18F-FDG PET/CT and 18F-FAPI PET/CT within 1 week. The maximum standard uptake value (SUVmax), tumor-to-background ratio (TBR), and diagnostic accuracy were compared between the two modalities. Results A total of 67 patients (57 men; median age, 57 [range, 32–83] years old) were included. 18F-FAPI PET showed higher SUVmax and TBR values than 18F-FDG PET in the intrahepatic lesions (SUVmax: 6.7 vs. 4.3, P < 0.0001; TBR: 3.9 vs. 1.7, P < 0.0001). In diagnostic performance, 18F-FAPI PET/CT had higher detection rate than 18F-FDG PET/CT in intrahepatic lesions [92.2% (238/258) vs 41.1% (106/258), P < 0.0001] and lymph node metastases [97.9% (126/129) vs 89.1% (115/129), P = 0.01], comparable in distant metastases [63.6% (42/66) vs 69.7% (46/66), P > 0.05]. 18F-FAPI PET/CT detected primary tumors in 16 patients with negative 18F-FDG, upgraded T-stages in 12 patients and identified 4 true positive findings for local recurrence than 18F-FDG PET, leading to planning therapy changes in 47.8% (32/67) of patients. Conclusions 18F-FAPI PET/CT identified more primary lesions, lymph node metastases than 18F-FDG PET/CT in HCC, which is helpful to improve the clinical management of HCC patients. Trial registration Clinical Trials, NCT05485792. Registered 1 August 2022, Retrospectively registered.

show abstract

Section: Methodsmentioning

confidence: 99%

Head-to-head comparison of 18F-FAPI and 18F-FDG PET/CT in staging and therapeutic management of hepatocellular carcinoma

Zhang,

Jiang,

et al. 2023

Cancer Imaging

View full text Add to dashboard Cite

show abstract

“…Fluorine-18-fluoro-2-deoxy-D-glucose positron emission tomography combined with computed tomography ( 18 F-FDG PET/CT) is a cutting-edge functional imaging method that provides images with higher resolution and concomitant anatomical information. 18 F-FDG PET/CT has been used as a diagnostic imaging modality for detection of prosthetic joint infection [ 16 , 17 ], Alzheimer’s disease [ 18 ], inflammatory and infectious vascular disease [ 19 ], and tumors [ 20 ]. Postsurgical infection is one of the most prevalent and challenging complications faced by orthopedic surgeons and patients, and clinical experience suggests that 18 F-FDG PET/CT may be promising for imaging of bone infections [ 21 – 24 ].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of vancomycin-releasing biodegradable poly(lactide-co-glycolide) antibiotics beads for treatment of experimental bone infection due to Staphylococcus aureus

et al. 2016

View full text Add to dashboard Cite

BackgroundClinical experience and animal studies have suggested that positron emission tomography (PET) using fluorine-18-labeled fluorodeoxyglucose (18F-FDG) may be promising for imaging of bone infections. In this study, we aimed to establish the accuracy of 18F-FDG PET scanning for monitoring the response to poly(lactide-co-glycolide) (PLGA) vancomycin beads for treatment of bone infection.MethodsPLGA was mixed with vancomycin and hot-compress molded to form antibiotic beads. In vitro, elution assays and bacterial inhibition tests were employed to characterize the released antibiotics. In vivo, cylindrical cavities were made in six adult male New Zealand white rabbits, and Staphylococcus aureus or saline was injected into the cavity to create a bone infection. After 2 weeks, the infection was confirmed by bacterial cultures, and the defect was filled with PLGA vancomycin beads. The treatment response was monitored by 18F-FDG PET.ResultsThe biodegradable beads released high concentrations of vancomycin (well above the breakpoint sensitivity concentration) for treatment of bone infection. In bacterial inhibition tests, the diameter of the sample inhibition zone ranged from 6.5 to 10 mm, which was equivalent to 12.5–100 % relative activity. 18F-FDG PET results showed that uncomplicated bone healing was associated with a temporary increase in 18F-FDG uptake at 2 weeks, with return to near baseline at 6 weeks. In the infected animals, localized infection resulted in intense continuous uptake of 18F-FDG, which was higher than that in uncomplicated healing bones. Bone infection was confirmed with positive bacterial cultures. In vancomycin-treated animals, data showed rapidly decreasing amounts of 18F-FDG uptake after treatment.ConclusionsIn vitro and in vivo analyses showed that the use of biodegradable PLGA vancomycin beads successfully eradicated S. aureus infection in damaged bone.

show abstract

PET/contrast-enhanced CT in oncology: “to do, or not to do, that is the question”

2022

View full text Add to dashboard Cite

FDG PET and Split-Bolus Multi–Detector Row CT Fusion Imaging in Oncologic Patients: Preliminary Results

Abstract: Fused FDG PET/split-bolus multidetector CT provides additional information compared with FDG PET/unenhanced multidetector CT in oncologic patients.

Cited by 4 publications

References 20 publications

Head-to-head comparison of 18F-FAPI and 18F-FDG PET/CT in staging and therapeutic management of hepatocellular carcinoma

Head-to-head comparison of 18F-FAPI and 18F-FDG PET/CT in staging and therapeutic management of hepatocellular carcinoma

Efficacy of vancomycin-releasing biodegradable poly(lactide-co-glycolide) antibiotics beads for treatment of experimental bone infection due to Staphylococcus aureus

PET/contrast-enhanced CT in oncology: “to do, or not to do, that is the question”

Contact Info

Product

Resources

About